Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine oral suspension in active eosinophilic esophagitis
NCT05488405Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Salcrozine in eosinophilic esophagitis (EoE), sponsored by Dr. Falk Pharma GmbH. Started Feb 2023; status: completed.
02
Drugs
Salcrozine
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05488405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488405.